B-synuclein promotes neurodegeneration
(proven target for potential therapies)
Please Help Support Alzheimer's Research Today!
Your Alzheimer's donation will help billions live without it.
A team of scientists from Japan and the University of California, San Diego School of Medicine have created a new mouse model that confirms that mutations of a protein called beta-synuclein promote neurodegeneration. The discovery creates a potential new target for developing treatments of diseases like Parkinson's and Alzheimer's. In 2004, La Spada discovered mutations in a family afflicted with a neurological disorder known as Dementia with Lewy Bodies. DLB is one of the most common types of progressive dementia, combining features of both Alzheimer's and Parkinson's diseases. Lewy bodies are abnormal aggregates of proteins. There are no known therapies to stop or slow the DLB's progression. There is no cure.
In the 2004 study, La Spada and colleagues found that mutations of the naturally occurring B-synuclein protein in DLB patients "were strong strongly suggestive of being pathogenic." That is, the mutated protein caused or was a cause of the disease. But the findings were not definitive. The newly published research describes the creation of a transgenic mouse model that expresses the B-synuclein mutation. The mice suffer from neurodegenerative disease, validating La Spada's earlier work. Read more: rdmag.com
Combining green tea polyphenols and a form of vitamin D called alfacalcidol may boost bone structure and strength, according to a new study in mice. Read more: nutraingredients.com
No comments:
Post a Comment